Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsGauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokineticsPrime Drug Interplay in Dental PracticeRenal drug transporters and their significance in drug-drug interactionsSimultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activitiesClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Telithromycin-induced digoxin toxicity and electrocardiographic changes.Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humansEffect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans.Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide.Drug interactions in the management of HIV infection.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Drug interactions during therapy with three major groups of antimicrobial agents.Drug-drug interactions involving membrane transporters in the human kidney.Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.Transporter-mediated drug-drug interactions.Renal Drug Transporters and Drug Interactions.The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model.Metameta-analysis.Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.Macrolide-induced digoxin toxicity: a population-based study.Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.Life-threatening drug interactions: what the physician needs to know.CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Absence of a clinically relevant interaction between etanercept and digoxin.PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
P2860
Q24631021-3BB41CBF-468E-47D2-B3B8-381DEA757961Q24656624-5F515B23-F602-43B2-BE56-65EE408D4169Q26748474-F46FDBB8-5D66-40AA-A4D8-26D2F176F607Q28071292-3A8F1731-BEC5-494C-8A3D-15F4D80566EAQ28269209-0AF845B2-B738-4E76-B114-26CD4097DAF1Q30234940-3BC920D0-22F4-4F13-B005-7CC6E6BEA0C2Q33153871-37E58273-2932-4FE0-94AE-BB527B58487AQ35212135-58EF0B7A-EC3C-499C-A492-8C7E2A613745Q35781981-3BD93644-0E0C-40F7-9DDA-2F6D64528B46Q35792862-F5149D8E-3586-4E05-8F74-F791883C0027Q35826832-0145B3BE-9B2C-466D-8D95-DAFFD5090DA7Q36024467-B40FC702-B6ED-48B5-8837-D7ED3A0E7F1DQ36066083-7F61158B-8C1F-4E3B-8E00-5F1E707D21DBQ36072448-39FF2C98-3FA4-4C9E-97FB-5378A93DA097Q36429699-4916B50E-6F09-42A1-9988-358B7499BA40Q36543091-04F9A129-CF85-40DB-BD3C-0A91A7BD8243Q37207759-3D47539A-F186-4F97-9082-68CED73CE0C8Q37492042-CA89F50C-A4A8-405A-8736-52E88C138DCBQ37726177-84D409C9-DFC2-41B0-A72D-E2A4BC0FEE0AQ37905033-6648C481-8131-44AE-B490-65F707833F90Q39140289-1D0F24C8-D747-4114-9F6E-E1E0CEEB1800Q39476375-D78F4ECF-4A0B-4C14-82AE-4271A2D03F4DQ42758702-AC2D956D-7D3B-412F-8D4C-D7DB9675E7D0Q45188831-11CBCF94-1564-44CC-88DF-08F3F451EFFCQ45928209-BD71794C-318E-405D-8FDF-281E5148974CQ46261836-083F3826-A79A-4DED-8339-394185B51C36Q48145727-78BD7E37-D731-4A41-B7A8-B09B7726577CQ49540092-0AA142AA-8315-420A-A41A-094172F25296Q50668713-57D4482E-8C2E-4038-9167-BCB357E0FFD1Q53632460-06723B0E-0937-46F4-A174-BAD6AB895639Q58758044-05DB42B9-7A09-4CB4-B80B-DE7DB86528D9
P2860
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Contribution of increased oral ...... xin-clarithromycin interaction
@en
Contribution of increased oral ...... xin-clarithromycin interaction
@nl
type
label
Contribution of increased oral ...... xin-clarithromycin interaction
@en
Contribution of increased oral ...... xin-clarithromycin interaction
@nl
prefLabel
Contribution of increased oral ...... xin-clarithromycin interaction
@en
Contribution of increased oral ...... xin-clarithromycin interaction
@nl
P2093
P2860
P50
P1476
Contribution of increased oral ...... xin-clarithromycin interaction
@en
P2093
Christoph Göggelmann
Ingeborg Walter-Sack
Jens Rengelshausen
Jochen Ludwig
Johanna Weiss
Klaus-Dieter Riedel
P2860
P356
10.1046/J.1365-2125.2003.01824.X
P407
P577
2003-07-01T00:00:00Z